Grifols, S.A.'s latest marketcap:
As of 07/05/2025, Grifols, S.A.'s market capitalization has reached $7.59 B. According to our data, Grifols, S.A. is the 2430th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 7.59 B |
| Revenue (ttm) | 7.97 B |
| Net Income (ttm) | 211.01 M |
| Shares Out | 680.41 M |
| EPS (ttm) | 0.31 |
| Forward PE | 10.85 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
Grifols, S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $7.59 B | 22.85% | 2430 |
| 12/31/2024 | $5.12 B | -35.64% | 2944 |
| 12/29/2023 | $7.95 B | 36% | 1978 |
| 12/30/2022 | $5.84 B | -24.31% | 2355 |
| 12/31/2021 | $7.72 B | -39.1% | 2247 |
| 12/31/2020 | $12.68 B | -20.82% | 1309 |
| 12/31/2019 | $16.01 B | 26.85% | 870 |
| 12/31/2018 | $12.62 B | -19.9% | 887 |
| 12/29/2017 | $15.76 B | 42.63% | 820 |
| 12/30/2016 | $11.05 B | -0.8% | 918 |
Company Profile
About Grifols, S.A.
Grifols, S.A. is a leading plasma therapeutics company operating globally, with a strong presence in Spain, the United States, Canada, and other international markets. The company specializes in developing and manufacturing life-saving plasma-derived medicines and diagnostic solutions.
Key Products & Services
- Immunoglobulins: Used to treat immunodeficiencies.
- Albumin: Restores circulatory volume in conditions like liver cirrhosis, trauma, and severe burns.
- Alpha-1 Proteinase Inhibitor: Treats genetic alpha-1 deficiency.
- Clotting Factors: Includes Factor VIII/von Willebrand factor and Factor IX for hemophilia A, von Willebrand's disease, and hemophilia B.
- Antithrombin III: Addresses hereditary antithrombin deficiency.
- Fostamatinib: A spleen tyrosine kinase inhibitor.
- Biological Sealants: Combines fibrinogen and thrombin to control surgical bleeding.
- Plasma Exchange Therapies: Used in Alzheimer’s disease treatment.
- Diagnostic Solutions: Equipment, reagents, and testing services.
Specialized Therapeutics
- Yimmugo IDP: Immunology drug.
- Yimmugo PTI: Hematology drug.
- Prolastin Vials: Pulmonology drug.
Innovation & Development
Grifols is actively advancing its pipeline with cutting-edge therapies, including:
- Xembify Pre-filled syringes, Gamunex Bags, and FlexBag.
- Xembify Biweekly dosing, Fibrinogen, and VISTASEAL.
- Prolastin-C AADT and Fostamatinib.
- Trimodulin, Alfa-1 AT 15%, and other pre-clinical stage treatments.
Collaborations & Partnerships
The company collaborates with organizations like Canadian Blood Services to supply immunoglobulin, reinforcing its commitment to global healthcare solutions.
Company Background
Founded in 1909, Grifols is headquartered in Barcelona, Spain, and continues to drive innovation in plasma-derived medicines and diagnostics.
Frequently Asked Questions
-
What is Grifols, S.A.'s (GRFS) current market cap?As of 07/05/2025, Grifols, S.A. (including the parent company, if applicable) has an estimated market capitalization of $7.59 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Grifols, S.A. (GRFS) rank globally by market cap?Grifols, S.A. global market capitalization ranking is approximately 2430 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.